UBS Downgrades Insmed (INSM) to Neutral; Arikayce Becomes a 2017 Story
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- GlobalFoundries and Marvell expand SiGe capacity for optical networking
Insmed Reports Third Quarter 2015 Financial Results and Provides Business Update
November 6, 2015 8:05 AM ESTBRIDGEWATER, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the third quarter and nine months ended September 30, 2015.
Business Update
Global Phase 3 ARIKAYCE study update. Patient enrollment continues in the companys global phase 3 study of ARIKAYCE (liposomal amikacin for inhalation or LAI) in nontuberculous mycobacteria (NTM) lung disease (CONVERT or INS-212 study). The company has secured health authority... More